Game on: Pfizer, BioNTech prepare to put COVID-19 shot distribution plan to the test after interim readout Pfizer, BioNTech set for billions in yearly sales as fast COVID-19 vaccine launch looms: analysts Eli Lilly wins FDA's emergency nod for COVID-19 antibody—but, thanks to mixed data, it's limited Prescription discount service SingleCare getting into home drug delivery CureVac climbs on vaccine data despite tolerability questions China's Sinovac hit by late-stage COVID-19 vaccine halt after reports of a death in Brazilian trial Kaiser generates $2B in Q3 earnings with patient volume rebound Adagio, 'firing on all cylinders,' grabs $80M for COVID-19 antibody Oak Street Health revenue jumps despite COVID-19 turbulence Biopharma roundup: CureVac posts early data; Sinovac trial halted Featured Story | By Kyle Blankenship In the first major breakthrough in the race for a COVID-19 vaccine, Pfizer and BioNTech unveiled early phase 3 data this week showing the shot's strong efficacy. Though other hurdles remain, the partners' lofty distribution plan could soon be put to the test—and nations are anxiously waiting to see whether they deliver. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky Pfizer's COVID-19 vaccine interim readout has spurred intense hope about quashing the pandemic and lifted expectations for other vaccine programs in the works. And for the drug giant specifically, some analysts are predicting billions in sales for the program in years to come. read more By Angus Liu The U.S. just authorized Eli Lilly's AbCellera-partnered COVID-19 antibody drug bamlanivimab for emergency use in mild-to-moderate patients who aren't hospitalized—so long as they're at "high risk" of serious disease. But just what is high-risk? That could confuse physicians, one analyst figures. read more By Paige Minemyer SingleCare, a company that offers prescription discounts to customers, is jumping into the hot home drug delivery market. read more By Nick Paul Taylor CureVac has presented more clinical data on its COVID-19 vaccine candidate. The results strengthen the impression that the vaccine triggers potentially protective immune responses while leaving scope to question whether CureVac can clear the bar set by its more advanced rivals. read more By Ben Adams Sinovac Biotech has seen a phase 3 trial of its pandemic vaccine hopeful Coronavac stopped in Brazil after reports of a serious safety concern, with one report stating a death is involved but was not in the vaccine arm. read more By Robert King Kaiser Permanente announced $2 billion in earnings last quarter, but the system's insurance business saw a decline due to major COVID-19 job losses. read more By Amirah Al Idrus In a time when speed is of the essence, Adagio Therapeutics is gathering steam. It picked up $80 million to propel its COVID-19 antibody into the clinic next year, just four months after launching with $50 million and a plan to go after multiple members of the coronavirus family. read more By Heather Landi Oak Street Health saw its revenue rise 57% to $218 million in the third quarter as its patient volume has grown despite the turbulent financial environment facing physician practices. The company has a new partnership with Walmart and aggressive plans to continue to open health centers throughout the country. read more By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner Germany's CureVac posted more early data for its mRNA vaccine candidate, but it isn't known yet whether the program will match the high efficacy bar set by Pfizer and BioNTech. Plus, a death in Brazil forced a trial halt for Sinovac, and the U.S. is working through plans to quickly begin vaccinations. read more |
